Alnylam Pharmaceuticalsvs.Gilead Sciences
ALNY vs GILD · both in Biotech & innovation, part of the Medicine, pharma & life science value chain: Innovation-driven biotech companies focused on novel treatment modalities.
Gilead Sciences is about 5.6× larger than Alnylam Pharmaceuticals by market cap; year to date, Gilead Sciences leads (+19.6% vs −40.6%).
Side by side
| ALNY | GILD | |
|---|---|---|
| Market cap | $30.4B | $170B |
| Price | $240.08 | $148.77 |
| Today | +1.7% | +1.4% |
| Return YTD | −40.6% | +19.6% |
| Return 1Y | −48.1% | +27.9% |
| P/E | 37.6 | — |
| P/S | 6.3 | 5.6 |
| P/B | 22.4 | 14.4 |
Data as of 2026-08-26 · updates daily after U.S. close
The two companies
Alnylam PharmaceuticalsALNY
Turns RNA interference into drugs, mostly for rare and cardiovascular disease.
Full ALNY profile →Gilead SciencesGILD
HIV treatment is the heart of it, Biktarvy above all, with cell therapy in oncology growing alongside.
Full GILD profile →More ALNY & GILD comparisons
Other head-to-heads in the Biotech & innovation segment.
See where ALNY and GILD sit in the full Medicine, pharma & life science map: every segment from suppliers to end markets.Open the Life science value chain →